Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Talsil Forte is an oral combination medication containing hydrotalcite, an antacid, and simethicone, an antifoaming agent. Developed and marketed by Juggat Pharma, it is indicated for the symptomatic relief of gastrointestinal disorders associated with hyperacidity and excess gas, including heartburn, gastroesophageal reflux disease (GERD), acute and chronic gastritis, acid dyspepsia, peptic ulcers, and flatulence. Hydrotalcite works by neutralizing excess gastric acid and raising stomach pH, while simethicone reduces the surface tension of gas bubbles in the gut, facilitating their coalescence and easy passage. This dual-action formulation is available as oral suspensions and chewable tablets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydrotalcite + simethicone.